Last updated: October 16, 2026
Capital paid for AI drug discovery three ways in one day: City Therapeutics priced an upsized $200.0 million IPO at $18.00, Iambic closed its first session at $18.91, up 18.2% from its $16.00 offer, and AstraZeneca signed insitro for AI enabled target discovery.
This article covers Thursday, October 15, 2026: the City Therapeutics pricing, Iambic’s first session, the AstraZeneca and insitro collaboration, the week’s clearing prices, MiniMed’s first bounce, ImmunityBio’s approval release, the 340B rebate litigation, the day’s readiness manufacturing contracts, and Vanda’s Phase 3 miss.
What did City Therapeutics price, and on what terms?
City Therapeutics priced an upsized initial public offering of 11,111,111 shares at $18.00 per share late Thursday evening, for gross proceeds of approximately $200.0 million, above the roughly $175 million the deal had targeted when terms were set. Shares begin trading on the Nasdaq Global Market on Friday, October 16 under the ticker CTY.
| Term | Detail |
|---|---|
| Shares offered | 11,111,111 (all primary) |
| Price | $18.00 per share |
| Gross proceeds | ~$200.0 million |
| Overallotment option | 1,666,666 shares, 30 days |
| Exchange / ticker | Nasdaq Global Market / CTY |
| First trade | Friday, October 16, 2026 |
| Expected close | October 19, 2026 |
| Book runners | Goldman Sachs, Jefferies, Stifel, Oppenheimer |
City is a clinical stage RNA interference company built on engineered triggers it calls cityRNA, with tissue selective delivery and genetics driven target selection. The lead program, CITY-FXI, targets thromboembolic disease; CITY-RBP4 targets Stargardt disease and other retinal diseases; CITY-TFR2 targets anemia associated with chronic disease. The pricing release carried no clinical data. The company was founded around RNAi trigger engineering and lists no approved products; the offering terms above come from the company’s pricing release, which crossed at 10:37 pm Eastern.
How did Iambic’s first trading session go?
Iambic closed its first session at $18.91, up 18.2% from the $16.00 offer price, by our arithmetic on the exchange settled close. It is the first IPO of this reopened window to finish its debut session at a meaningful premium rather than at or below face value. The IPO’s closing is expected Friday, October 16.
Fierce Biotech’s report on the completed offering details how the roughly $150 million in gross proceeds will be spent. Of about $125 million allocated, $75 million goes to IAM1363, an oral brain penetrant HER2 inhibitor in Phase 1 for HER2 altered solid tumors with Phase 2 and Phase 3 studies planned; $15 million takes IAM217, a brain penetrant KIF18A allosteric inhibitor, into the clinic for ovarian cancer, triple negative breast cancer and other solid tumors; $15 million funds a Phase 1 study of IAM-C1, a dual CDK2/4 inhibitor aimed at breast cancer and CCNE1 amplified tumors; and $20 million goes to the company’s AI platform, including new versions of its Enchant and NeuralPLexer models. Per the same report, Iambic held $207.9 million in cash at the end of June and has said its funding lasts through the end of 2028.
What did AstraZeneca agree to pay insitro, and for what?
AstraZeneca signed insitro to an AI enabled target discovery collaboration in metabolic dysfunction associated steatohepatitis (MASH) and cardiomyopathies. As reported by Fierce Biotech, the deal carries a $40 million upfront payment and up to $1.46 billion in development and commercial milestones; the figures were not independently confirmed from a primary release in our fetch scope, and headlines rounding the package to $1.5 billion are rounding those components. AstraZeneca takes exclusive worldwide rights to advance selected programs.
insitro’s platform combines human and cellular data with machine learning to identify causal disease biology. CEO Daphne Koller called MASH and cardiomyopathies prevalent, underdiagnosed diseases where high content data gives strong signal for finding disease drivers. The deal extends a partner list that already includes Gilead (2019, in NASH as the field then called it), Bristol Myers Squibb (2020, since extended) and Eli Lilly (2024). insitro raised $400 million in 2021.
| insitro partner | Year | Focus |
|---|---|---|
| Gilead | 2019 | Liver disease (NASH) |
| Bristol Myers Squibb | 2020, extended | Neuroscience |
| Eli Lilly | 2024 | Metabolic disease |
| AstraZeneca | 2026 | MASH, cardiomyopathies |
The structure is the tell: a $40 million upfront for target discovery, as reported, is platform validation money, not asset money. The same market that paid a 30% equity premium inside Gilead’s Vir deal on Tuesday put its capital behind AI discovery at three separate price points on Thursday: a partnership upfront, a first session premium, and an upsized pricing.
How did the week’s clearing prices grade?
Every event this week cleared at a price, and the week ended with the first genuine premiums of the window. The scoreboard below collects the settled closes that graded each event; percentages are our arithmetic on exchange settled closes.
| Event | Clearing price | Read |
|---|---|---|
| J&J Q3 beat and raise (Oct 14 print, Tue) | Cleared −5.7%, retraced +2.1% Wed, −0.2% Thu | Growth quality tax, then stabilization |
| Liquidia settlement ($380.7M net) | +26.6% Wed, +2.5% Thu to 34.78 | Certainty premium, held |
| Biomea partner search | −33.8% Wed, +0.3% Thu at 0.8364 | Partner dependent assets clear at distress |
| MiniMed exchange (final 18.289133% proration) | −8.6% Wed, +7.1% Thu to 18.00 | First bounce; settlement timing unannounced |
| Iambic IPO ($16.00) | First session close 18.91, +18.2% | First debut premium of the window |
| TRexBio / Retension aftermarket | TRXB 14.16 (+4.9%), RTSN 12.21 (+4.9%) | Both reclaimed ground; RTSN now above its $12 offer |
| City Therapeutics pricing | $18.00, upsized to ~$200.0M | Demand above the ~$175M target |
Monday’s framework said cash clears at face value for certainty and negotiates for everything else. Thursday is the first session this month where the tape paid premiums across the board: the new issue, the aftermarket, and the sector (XBI +2.1% on SPY +0.3%). Whether that is a repricing of biotech risk or one strong session will be answered by where City opens Friday and whether Iambic holds $18.91 through its closing date.
What happened to MiniMed’s stock after the exchange closed?
MMED closed at 18.00 Thursday, up 7.1% from Wednesday’s 16.81, the first up session since the final proration printed. Medtronic closed at 95.45, up 1.3%. The package math moves accordingly: 4.5939 MMED shares per accepted Medtronic share were worth $82.69 against Medtronic’s 95.45 close, a gap of roughly 13.4%, narrowed from about 18 points Wednesday; both figures are our arithmetic on settled closes.
The label still matters: Medtronic’s final results release said shares would be credited promptly, and no settlement completion notice had appeared in our scope by Thursday night (searches plus the Medtronic newsroom index). Until the distribution is confirmed complete, the tape remains a transition tape, not a settled float. Wednesday’s read was that the slide into certainty looked like the market pre selling the float; Thursday was the first evidence against that read, and we said the verdict window is the first full week of real float trading. It still is. Sixteen held.
What did ImmunityBio’s own release add to the Anktiva approval?
The primary is now in hand. ImmunityBio’s October 14 press release, filed as an 8-K exhibit, frames the action as the FDA expanding the Anktiva approval to cover both papillary and CIS disease in BCG unresponsive non muscle invasive bladder cancer, building on the April 2024 CIS approval. The release cites the Quilt-3.032 CIS cohort: a 62% complete response rate in 77 patients (95% CI: 51, 73), with 58% of responders maintaining response at least 12 months and 40% at least 24 months.
One correction from our Thursday edition: reporting the approval through trade coverage, we printed a 48% twelve month duration figure among complete responders. The company’s own release states 58% at twelve months. The 24 month figure of 40% matches. The release cites no papillary only efficacy data at all, consistent with the FDA’s announcement; the approval rests on extrapolation from the CIS cohort, which is the precedent that matters. The release notes papillary disease represents about 85% of the NMIBC population, which is the commercial point: the extrapolated indication is the larger one. IBRX closed at 10.00, up 0.9%, a second muted session. The FDA’s own notice page had still not surfaced in our searches by Thursday night.
Who is fighting over the 340B rebate pilot?
The drug industry moved to defend a government drug pricing program in court this week, which tells you how the 340B fight has inverted. As reported by Fierce Healthcare: the American Hospital Association, the Maine Hospital Association and three providers sued HHS and HRSA on October 9 in the District of Maine to block the 340B Rebate Model Pilot Program, which from January 1 would replace upfront 340B discounts with after the fact rebates across 21 drugs from 10 manufacturers. On Wednesday AbbVie, Bristol Myers Squibb and Boehringer Ingelheim moved to intervene on the government’s side; on Thursday PhRMA followed.
| Date | 340B rebate pilot event |
|---|---|
| Early 2026 | First version blocked by the same court; HRSA withdrew it for a longer comment process |
| July 2026 | Final guidance: manufacturers build and maintain the rebate IT systems |
| Oct 9 | AHA, Maine Hospital Association and three providers sue HHS and HRSA (D. Maine); TRO requested |
| Oct 14 | AbbVie, Bristol Myers Squibb, Boehringer Ingelheim move to intervene |
| Oct 15 | PhRMA moves to intervene |
| Jan 1, 2027 | Pilot launch date |
Hospitals estimate more than $1 billion per year in added administrative costs; HRSA’s own estimate is about $537.2 million per year across covered entities; both figures per the reporting above. PhRMA argued a lack of a rebate model led Boehringer to pay millions of dollars per week in duplicate discounts early this year. The same trade group is simultaneously the plaintiff against CMS over the GLOBE most favored nation model, where no new docket activity surfaced in our scope this week. The industry’s litigation posture on drug pricing now runs in both directions at once: suing to stop a price referencing model, intervening to save a rebate model.
What did Galapagos get for its cell therapy pipeline?
Lakefront Biotherapeutics, the company formerly named Galapagos, sold its preclinical cell therapy portfolio to Armed Cell Therapeutics, the Belgian startup founded by former Galapagos CEO Paul Stoffels. As reported by Fierce Biotech from the companies’ release: 8 million euros (about $9 million) upfront plus up to $230 million in back loaded milestones, for multi targeting and armed CAR T constructs tracing to the AboundBio acquisition Galapagos made for $14 million in 2022. Fierce’s reporting puts the financial hit from closing the cell therapy business at about 228 million euros ($269 million), with roughly 365 employees affected across Europe, the US and China.
The shape of the exit says more than the size. A pipeline that consumed a multiyear strategic pivot cleared at single digit millions upfront, to the executive who originally championed it, after a sale process that ran for most of a year. That is the same clearing price logic that marked Biomea’s partner search this week: clinical and preclinical cell therapy without a committed partner clears at distress, while discovery platforms upstream of the clinic get $40 million handshakes. Capital has a strong opinion about where in the pipeline risk should live.
What moved in readiness manufacturing on Thursday?
Three stories served the manufacturing and supply chain beat. Kindeva’s Meridian Medical Technologies unit won a Defense Logistics Agency contract worth up to $226 million for up to 3 million ATNAA nerve agent antidote autoinjectors, the military version of its civilian DuoDote dual chamber injector of atropine and pralidoxime chloride, per Fierce Pharma citing the company’s release; it follows the roughly $129 million civilian DuoDote award through ASPR finalized in late 2025.
NorthStar Medical Radioisotopes named Beijing based CRO Quarkmed its registration agent in China, providing dossiers so drug developers can file China INDs using NorthStar’s no carrier added actinium 225, produced on electron accelerator technology in Beloit, Wisconsin. No financial terms were disclosed. The deal extends a run that includes commercial scale actinium production reached in January and an up to $185 million Hercules Capital facility in late September, $100 million available upfront, per Fierce Pharma’s reporting. US produced alpha isotopes are becoming an export product precisely as radiopharma pipelines globalize.
And Par Health recalled 22 lots of potentially contaminated IV blood thinner bags, its third recall this month, per Fierce Pharma. Sterile injectables quality remains the sector’s recurring operational tax.
Why did Vanda’s social anxiety drug fail?
VQW-765, an alpha 7 nicotinic acetylcholine receptor partial agonist Vanda licensed from Novartis in 2014, missed the primary endpoint of its Phase 3 study in social anxiety disorder. The design was unusual: 546 adults took a single oral dose and then performed a public speaking stress test before a panel giving no feedback. The primary analysis was restricted to women, based on a midphase signal, and distress scores in women on drug were no better than placebo; a secondary endpoint across all patients also missed. Vanda paused the program pending full data. No effect size figures were published in the coverage we reviewed.
The tape’s response was the story: VNDA closed at 4.24, up 0.5%. A Phase 3 failure that moves a stock nothing is a readout the market had already written to zero, and a sex restricted primary endpoint adopted midstream is the kind of design the market has learned to discount before the data arrive. Vistagen’s fasedienol failed twice in the same indication within the past year; acute use social anxiety pharmacology keeps failing the transition from signal to significance.
Which stocks moved on Thursday, October 15?
Settled closes; percentages are our arithmetic. Moves listed carry a story; routine moves are omitted.
| Ticker | Close | Move | Context |
|---|---|---|---|
| IAM | 18.91 | +18.2% vs $16.00 offer | First session; first debut premium of the window |
| MMED | 18.00 | +7.1% | First bounce after the final proration; settlement timing unannounced |
| TRXB | 14.16 | +4.9% | Reclaimed its post closing slide |
| RTSN | 12.21 | +4.9% | Back above the $12 offer; closing release still absent |
| LQDA | 34.78 | +2.5% | Certainty premium held a second session |
| FRNM | 12.285 | +0.8% | First up session after three declines |
Sector context: XBI closed 149.78, up 2.1%, on SPY up 0.3%.
Frequently asked questions
What price did City Therapeutics’ IPO price at?
$18.00 per share for 11,111,111 shares, roughly $200.0 million gross, upsized from a deal that had targeted about $175 million. CTY begins trading on the Nasdaq Global Market on Friday, October 16, 2026, with closing expected October 19.
What does City Therapeutics do?
It is a clinical stage RNA interference company using engineered cityRNA triggers with tissue selective delivery. Lead program CITY-FXI targets thromboembolic disease; CITY-RBP4 targets Stargardt and other retinal diseases; CITY-TFR2 targets anemia of chronic disease.
How did Iambic stock perform on its first day of trading?
IAM closed its October 15 debut at $18.91, up 18.2% from the $16.00 IPO price by our arithmetic, the first debut session premium of the current biotech IPO window. The offering’s closing is expected October 16.
How much is the AstraZeneca insitro deal worth?
As reported by Fierce Biotech, $40 million upfront plus up to $1.46 billion in milestones for AI enabled target discovery in MASH and cardiomyopathies, with AstraZeneca taking exclusive worldwide rights to selected programs. The components were not confirmed from a primary release in our scope.
What diseases will AstraZeneca and insitro work on?
Metabolic dysfunction associated steatohepatitis (MASH) and cardiomyopathies, both areas where insitro argues high content human and cellular data can expose causal biology that conventional target selection misses.
Did the MiniMed distribution settle yet?
No completion notice had appeared by Thursday night. Medtronic’s final results release said exchanged shares would be credited promptly; MMED’s +7.1% session to 18.00 is still a transition tape until settlement is confirmed.
What is the final MiniMed exchange proration factor?
18.289133%, per Medtronic’s final results release of October 14. Medtronic accepted 55,032,401 of its shares and is exchanging its entire remaining MiniMed stake, retaining none.
What did ImmunityBio’s Anktiva release say about papillary efficacy?
Nothing; it cites only the CIS cohort of Quilt-3.032 (62% complete response in 77 patients, 58% of responders at 12 months, 40% at 24 months) and frames the papillary coverage as an expansion resting on extrapolation. It notes papillary disease is about 85% of NMIBC.
What is the 340B rebate pilot and who opposes it?
An HHS and HRSA pilot replacing upfront 340B discounts with after the fact rebates for 21 drugs from 10 manufacturers starting January 1. Hospital groups sued to block it; AbbVie, Bristol Myers Squibb, Boehringer Ingelheim and PhRMA moved to intervene in its defense.
Who bought Galapagos’ cell therapy assets?
Armed Cell Therapeutics, the Belgian biotech founded by former Galapagos CEO Paul Stoffels, for 8 million euros upfront plus up to $230 million in milestones, per the companies’ announcement as reported by Fierce Biotech. Galapagos itself is now named Lakefront Biotherapeutics.
What contract did Kindeva win?
Its Meridian Medical Technologies unit won a Defense Logistics Agency contract worth up to $226 million to supply up to 3 million ATNAA nerve agent antidote autoinjectors, per Fierce Pharma citing the company’s release.
Why did Vanda’s VQW-765 fail in social anxiety?
The Phase 3 single dose study missed its primary endpoint in women, the population Vanda selected from a midphase signal, and a broader secondary endpoint also missed. The program is paused pending full data; no effect sizes were published.
What did OMass Therapeutics raise?
A $310 million Series C co led by Bain Capital Life Sciences, Forbion and Novo Holdings, per Fierce Biotech, the second largest European biotech round of 2026. Lead program OMS1620, an MC2 receptor antagonist, heads to Phase 2 in congenital adrenal hyperplasia and ACTH dependent Cushing’s syndrome.
When does Abbott report Q3 2026 earnings?
Wednesday, October 21, 2026, with results before the market opens and a call at 8 am Central, per Abbott’s September 30 announcement.
Sources
Primary sources: City Therapeutics IPO pricing release (GlobeNewswire, October 15, 2026); ImmunityBio press release, October 14, 2026 (8-K exhibit 99.1, SEC); Medtronic final exchange offer results release (news.medtronic.com, October 14, 2026); Abbott third quarter earnings call announcement (September 30, 2026); exchange settled closing prices, October 15, 2026.
Trade press and other coverage (attributed): Fierce Biotech (AstraZeneca and insitro; Iambic IPO completion; Lakefront and Armed Cell; OMass Series C; Vanda VQW-765); Fierce Pharma (Kindeva and Meridian DLA contract; NorthStar and Quarkmed; Par Health recall); Fierce Healthcare (340B rebate pilot litigation); Endpoints News (OrbiMed funds; Osivax Phase 2b headline); MedTech Dive (Siemens Healthineers ultrasound exit, October 14 article on the October 12 announcement); Renaissance Capital and IPO Buzz (City Therapeutics terms context).
Checks run without result (scope and timestamp, October 15 night): Retension IPO closing release (searches; StockTitan news index); MiniMed settlement completion notice (searches; Medtronic newsroom items via search); GENEROUS participation final count (cms.gov newsroom through October 15); PhRMA v CMS GLOBE docket activity (searches; latest coverage October 7 to 8); US price disclosures for Atebrioz, Weltruza and Hovilpri (searches); the FDA’s Anktiva approval notice page (searches; two stale investor relations pages identified and discarded).
Related coverage
Read our Thursday briefing on the Anktiva extrapolation approval, the MiniMed final proration and Liquidia’s first reaction, our Wednesday briefing on J&J’s quarter and the Liquidia settlement, and our Tuesday briefing on First Tracks’ celiac data and Bristol Myers’ two pivotal wins.
